SMOKING AND BRAIN DERIVED NEUROTROPHIC FACTOR (BDNF) LEVEL IN SERUM

BY

Laila M. El Zalabany, Doaa A. El Morsi, Sahar A. EL Dakroory, Alyaa Aba El-Hassan and Amany Ragab Yousef*

Departments of Forensic Medicine and Clinical Toxicology and Clinical Pathology*
Mansoura Faculty of Medicine - Egypt

ABSTRACT

Brain derived neurotrophic factor (BDNF) is a member of neurotrophins which are a family of proteins whose action influence neurons of the central nervous system. The aim of the present study is to compare the differences in serum BDNF level in smokers and nonsmokers to better clarify the relationship between smoking and BDNF. The BDNF is measured in 88 subjects chosen randomly (33 non smokers and 55 smokers). All subjects are free from any chronic physical disease, allergy, psychiatric disorders and regular medications. A self-made questionnaire is given to each subject stating the age, amount of cigarette use (no. of cigarette / day), age of the first use and duration of use. Body mass index are calculated. In addition, Fagerstrom test for nicotine dependence (FTND) and smoking index are calculated. The results reveal no significant difference between BDNF level in smokers and non smokers. It is concluded that although BDNF level in the present study does not show any significant difference between smokers and non-smokers, this relationship needs further researches to be established and future studies will need to recruit more subjects in order to increase the statistical power of the research.

Key words: Neurotrophines, BDNF, Smoking, Nicotine, Drug of abuse.

INTRODUCTION

Tobacco use is associated with five million deaths per year worldwide and is regarded as one of the leading causes of early death (Hatsukami et al., 2008). Nicotine is the primary addictive component of tobacco and most people who smoke regularly develop nicotine dependence. Although nicotine is not generally classified as one of the strong addictive drugs such as cocaine and heroin, cigarette smoking is often a very difficult habit to break (Kim et al., 2007).

Neurotrophins are a family of proteins whose action influence neurons of the central nervous system (Huang and Reichardt, 2001). Neurotrophins family in mammals consists of four members: nerve growth factor (NGF), BDNF, neurotrophin 3 (NT-3) and neurotrophin 4/5 (NT-4/5) (Bertaux et al., 2004).
It was found that under normal circumstances, the biological response of neurotrophins through their receptors include proliferation and survival; axonal and dendritic growth, synapse formation, function and plasticity. Under pathological circumstances, the level of pro-neurotrophins increase thus resulting in increased neuronal, dendritic and synaptic apoptotic deterioration (Buckley et al., 2007).

Brain derived neurotrophic factor is a member of neurotrophines which is one of the most abundant neurotrophic factors in the brain. It is widely expressed in the hippocampus, septum, cortex, and in adrenergic brain stem nuclei (Chao et al., 2006). The alteration of BDNF has been found to modulate several addictive behaviors associated with the actions of certain drugs of abuse (Bhang et al., 2010).

Recently BDNF which has been intensely investigated in the context of depression and anxiety disorders became also a target to examine the biological underpinnings of nicotine dependence (Groves, 2007).

A study done on humans by Kim et al. (2007) found that measured serum levels of BDNF in smokers and non-smokers support the notion of a possible relation between BDNF and smoking. They found that the smoking group had significantly lower BDNF baseline with a significantly higher rise of BDNF serum levels after two months of smoking cessation. However, there were few investigations concerning the changes in BDNF levels during chronic exposure to or withdrawal from cigarette smoking in clinical subjects with nicotine dependence.

In animal studies, regional brain BDNF expression was altered by exposure to or withdrawal from nicotine. Several animal studies suggest that BDNF plays an important role in drug addiction. Among these, the study done by Horger et al. (1999) which reported that the infusion of BDNF into the nucleus accumbens lead to enhanced cocaine-conditioning. These findings suggest that BDNF acts upon the reward system of the brain, which plays a key role in drug addiction (Goldstein and Volkow, 2002).

In the present study, the differences in BDNF level in smokers and nonsmokers is compared to better clarify the relationship between smoking and BDNF.

**SUBJECTS & METHODS**

**Subjects:** In the present study 88 subjects were chosen randomly (33 non-smokers and 55 smokers). All subjects were free from any chronic physical disease, allergy, psychiatric disorders and regular medications. In addition, a self - made question-
El Zalabany et al ...

naire was given to each subject stating the age, amount of cigarette use (no. of cigarettes / day), age of first use and duration of use. Also the height and weight were measured to calculate body mass index (BMI) (Weight / Height²). In addition, Fagerstrom test for nicotine dependence (FTND) (Heatherton, 1991) and smoking index (No. of cigarettes / day X No. of years of smoking) (Matsubara et al., 2002) were calculated.

**Fagerstrom Nicotine Dependence Scale (FTND):**

1. How soon after you wake up do you smoke your first cigarette?
   a. Within 5 minutes (3 points)
   b. Within 6-30 minutes (2 points)
   c. Within 31-60 minutes (1 point)
   d. After 60 minutes (0 points)

2. Do you find it difficult to refrain from smoking in places where it is forbidden (e.g. at the library, in cinema, etc)?
   a. Yes (1 point)
   b. No (0 points)

3. Which cigarette would you hate most to give up?
   a. The first one in the morning (1 point).
   b. Any other (0 points).

4. How many cigarettes per day do you smoke?
   a. 10 or less (0 points)
   b. 11-20 (1 point)
   c. 21-30 (2 points)
   d. 31 or more (3 points)

5. Do you smoke more during the first hours after waking than during the rest of the day?
   a. Yes (1 point)
   b. No (0 points)

6. Do you smoke even when you are ill enough to be in bed most of the day?
   a. Yes (1 point)
   b. No (0 points)

A score of 5 or more indicates a significant dependence, while a score of 4 or less shows a low to moderate dependence.

**Sampling:** Three ml blood samples were collected from each subject after taking informed consent to measure BDNF concentration. Samples are allowed to clot for 30 minutes then centrifuged for 15 minutes at 1000 Xg and stored at -40°C till the analysis.

**Sample preparation:** Polypropylene tubes were used to dilute the serum samples 20 folds by the use of the calibrator diluents just prior to the assay. 10 µl serum was added to 190 µl calibrator diluents RD6P (Barakat-Walter, 1996).

**Principle of the assay:** This assay emp-
lys the quantitative sandwich enzyme immunoassay technique by the use of "quantikine" R & D systems, Inc. Minneapolis, USA. A monoclonal antibody specific for BDNF has been pre-coated onto a microplate standard, samples are pipetted into the wells and any BDNF present is bound by the immobilized antibody. Following a wash to remove any unbound antibody enzyme reagent, a substrate solution is added to the wells and color develops in proportion to the amount of BDNF bound in the initial step. The color development is stopped and the intensity of the color is measured by the Enzyme Linked Immunosorbent Assay (ELISA) reader set at 450 nm with wavelength correction set at 570 nm (Kokaia et al., 1996).

Statistical analysis: The statistical analysis of data done by using Excel program and SPSS program statistical package for social science version 10. To test the normality of data distribution, K-S (Kolmogorov-Smirnov) test was done only significant data revealed to be nonparametric.

N. B.: all tested data revealed to be parametric.

The description of the data done in the form of mean ± SD for quantitative data; frequency and proportion for qualitative data. The analysis of the data was done to test statistical significant difference between groups. One way ANOVA test to compare more than two groups. For quantitative data student t-test was used to compare between two groups. Chi-Square test ($\chi^2$) was used for qualitative data. Correlation coefficient was done to detect association between variables. p is significant < 0.05.

RESULTS

Table (1) shows the baseline characteristics of smokers (n = 55) and non smokers (n = 33). Significant difference between the age of smokers and non-smokers; the mean ± SD of age in smokers and non-smokers is (33.672 ± 7.710 & 29.303 ± 3.432 years) respectively. Also there is significant difference of BMI between smokers and non-smokers. The mean ± SD of BMI in smokers and non smokers is (26.768 ± 3.583 & 25.030 ± 4.107 kg / m$^2$) respectively. The mean ± SD of BDNF level in smokers and non smokers is (20402.04 ± 10494.057 & 18390.67 ± 9331.521 pg / ml) respectively but non significant. As regards the smokers; the mean ± SD of age of first use of cigarette is 20.4545 ± 5.5103 years and the mean ± SD of duration of use is 21.4727 ± 13.5767 years and the mean ± SD of the amount of use is 13.2545 ± 6.6031 cigarette / day. By studying the FTND and smoking index they are (4.272 ± 2.272 & 15.2755 ± 12.971) respectively.

Figure (1): Demonstrates positive correlation between BDNF and age of the first
use. The youngest the age of the first use; the highest the BDNF level in serum.

**DISCUSSION**

Growth factors are required for the normal development and functioning of the nervous system. One group of growth factors includes the neurotrophins, a family of secretory proteins, consisting of nerve growth factor, brain-derived neurotrophic factor (BDNF), neurotrophin-3, and neurotrophin - 4/5. Of the neurotrophins, BDNF plays a significant role in the promotion of normal nervous system development, and in regulating cell survival and apoptosis (Balkowiec and Katz, 1998).

In the present study, the differences in serum BDNF level in smokers and non-smokers to better clarify the relationship between smoking and BDNF level.

Furthermore, no correlations were found between the plasma BDNF levels and the demographic or smoking-related clinical variables in the smoker group except for the positive correlation found between the age of the first use and the BDNF level. There were significant difference between smokers and non-smokers as regard the age and BMI. However the BDNF level was found to be higher in smokers than in non-smokers but this difference was statistically insignificant. To our knowledge, there are few studies which investigate the changes in the plasma BDNF levels of clinical subjects with nicotine dependence.

The results of Kenny et al. (2000) showed that acute administration of nicotine decreases BDNF level whereas chronic nicotine increases BDNF levels in the hippocampus. On the other hand, Zhang et al. (2010) stated that BDNF levels were significantly higher in smokers than in non-smokers (p < 0.05).

A study done by Thomas et al. (2008) found that the kinetics of BDNF expression by nicotine exposure in animal studies remain controversial because it has been suggested that acute exposure to nicotine typically decreases BDNF levels in contradiction to a previous study that demonstrated an increase in BDNF expression by long-term nicotine exposure (Kenny et al., 2000). Considering the function of BDNF, this finding might be indicative of a breakdown in an endogenous neuroprotective mechanism or of continuous functional down-regulation of BDNF by chronic smoking.

However, the present results are inconsistent with the findings of a previous proteomic analysis in the rat brain in which BDNF expression was decreased at both the protein and mRNA levels by repeated exposure to nicotine (Yeom et al., 2005).
On contrary to the present study Bhang et al. (2010) reported that baseline serum BDNF levels were significantly lower in smokers compared to non-smokers (F=4.410, p=0.002). The same findings were noticed in Kim et al. (2007) who stated that the baseline serum BDNF levels in smokers were significantly lower than those in non-smokers (F=4.626, p=0.038).

A limitation to this study is that the BDNF levels were measured in the serum, and although it has been reported that BDNF may cross the blood-brain barrier (Pan et al., 1998), yet this hypothesis has not been confirmed. Although certain amounts of BDNF are stored in platelets and subsequently released, it is believed that a major portion of human plasma BDNF may originate from the brain (Fuji-mura et al., 2002).

It could be concluded that the relationship between BDNF level and smoking needs further researches to be established and one limitation of the present study is that the sample size was relatively small. Future studies will need to recruit more subjects in order to increase the statistical power of the research.
Table 1: Baseline characteristics of smokers (n = 55) & non smokers (n = 33).

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Smokers (N = 55) Mean ± SD</th>
<th>Non Smokers (N = 33) Mean ± SD</th>
<th>Range</th>
<th>t</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Demographics</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age (years)</td>
<td>33.672 ± 7.710</td>
<td>29.303 ± 3.432</td>
<td>3.073</td>
<td>0.003**</td>
<td></td>
</tr>
<tr>
<td>Body Mass Index (Kg / m²)</td>
<td>26.768 ± 3.583</td>
<td>25.030 ± 4.107</td>
<td>2.085</td>
<td>0.040 **</td>
<td></td>
</tr>
<tr>
<td>BDNF level (pg / ml)</td>
<td>20402.04 ± 10494.057</td>
<td>18390.67 ± 9331.521</td>
<td>0.906</td>
<td>0.367</td>
<td></td>
</tr>
<tr>
<td>Smoking Related data</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age of first use (years)</td>
<td>20.4545 ± 5.5103</td>
<td></td>
<td>9 - 35</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Duration of use (years)</td>
<td>21.4727 ± 13.5767</td>
<td></td>
<td>3 - 30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Amount of use (Cigarettes / d)</td>
<td>13.2545 ± 6.6031</td>
<td></td>
<td>5 - 60</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Scores of FTND</td>
<td>4.272 ± 2.272</td>
<td></td>
<td>1 - 8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Smoking index</td>
<td>15.2755 ± 12.971</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**FTND** = Fagerstrom Test for Nicotine Dependence. Significant level at p < 0.05.
Figure (1): Correlation between BDNF concentration in blood and age of the first use of cigarette.
REFERENCES


التدخين ومستوى عامل النيوروتروفين المستمدة من المخ في السيرم

المشتركين في البحث

أ. د. ليلي محمد الزبلياني
أ. د. سحر عبدالعزيز الدكوري
أ. د. أماني يجب يوسف

من قسم الطب الشرعي والسموم الإكلينيكية والباثولوجيا الإكلينيكية
كلية الطب - جامعة المصرية

بعد النيوروتروفين من عائلة النيوروتروفينات وهي مجموعة من البروتينات التي تؤثر على حيوية ونمو وشكل الخلايا العصبية للجهاز العصبي المركزي، ويهدف هذا البحث إلى المقارنة بين مستوي النيوروتروفينات في السيرم في المدخنين مقابل غير المدخنين، وقد تم بذل الدراسة على 88 شخص (35 من غير المدخنين و55 من المدخنين) تم إختبارهم عشوائياً وجمع الأشخاص محل الدراسة لليافعين من أمراض عضوية مزمنة أو حساسية أو أمراض نفسية ولا يشترطون أي عقاقير، وتم أخذ 3 مللي دم من كل شخص بعد أخذ موافقة كتبية منهم لقياس مستوي عامل النيوروتروفين المستمدة من المخ بها، وقد تم مليء إستبيان عن العمر وعدد السجائر التي يتم تدخينها في اليوم والعمر الذي يتم تدخين أول سيجارة به وعدد سنوات التدخين وكذلك تم قياس الطول والوزن حساب عمر كتلة الجسم وحساب فيرستور للمدخنين وعظام التدخين، وقد أثبتت الدراسة وجود إرتفاع في متوسط مستوي عامل النيوروتروفين المستمدة من المخ في المدخنين وغير المدخنين ولكنه ليس له دلالة إحصائية، ويمكن أن نستخلص أنه بالرغم من أن مستوي النيوروتروفين المستمدة من المخ في هذه الدراسة لم يظهر أي إختلاف ذو دلالة إحصائية بين المدخنين وغير المدخنين لهذه العلاقة تحتاج العديد من الأبحاث لتنبئها، كما يجب أيضًا زيادة حجم العينة محل الدراسة لزيادة القوة الإحصائية للبحث.